The Citizens Commission on Human Rights (CCHR) is urging consumers to read psychotropic drug labels for warnings about suicide, aggression, and homicidal ideation, and to ask their prescribing physicians to explain these risks, even if they are listed as rare. The call follows recent news reports of violent crimes in which individuals were reported to be taking or withdrawing from prescribed antidepressants, stimulants, or other psychiatric drugs with documented side effects of aggression, homicidal ideation, and suicidal behavior.
CCHR's decades-long campaign has highlighted these risks, leading U.S. and foreign regulators to require warnings on various psychiatric drugs. Jan Eastgate, president of CCHR International, emphasized that "a rare warning buried in a package insert is not the same as a doctor explaining the risk to a patient." She stressed that meaningful informed consent requires meaningful disclosure and prescriber accountability.
The issue is also being debated in legal and psychiatric circles. Psychiatric Times recently published an article discussing whether psychiatrists are responsible for their patients' criminal behavior, noting that litigation in such cases "places psychiatrists and other mental health providers under scrutiny."
CCHR's compilation of international regulatory agency warnings shows a dramatic increase: 57 warnings or safety notices since 2004 involving violence, aggression, or hostility, compared to five in 2004—a 1,040% increase. Thirteen of these notices specifically reference homicidal ideation or thoughts of harming others. Examples include the addition of homicidal ideation to venlafaxine labeling in 2005, a boxed warning for bupropion in 2009, and a class-wide warning for stimulants in 2023.
Eastgate noted that the existence of a warning in drug labeling does not ensure that a patient was adequately informed. "A judge allowing a jury to hear evidence about prescription drugs is not the same as a physician warning a patient before the first dose," she said.
The concern has entered public policy. A 2026 Tennessee law requires toxicology testing for psychiatric and other drugs following specified violent incidents, and CCHR has called for similar laws nationwide.
Eastgate concluded: "While not all individuals taking a prescription psychotropic drug will become violent or suicidal, they should read these warnings and ask questions before agreeing to treatment. Prescribers should explain potentially serious violent and suicidal adverse effects—including those considered rare—and document that the patient was given the information necessary to make an informed decision."
CCHR, established in 1969, maintains that transparent disclosure of known risks and prescriber accountability are fundamental to meaningful informed consent. Patients are advised not to abruptly stop taking psychiatric drugs without medical supervision.
